DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...
Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...
The circuit is simple, economical, and built using easily sourced, budget-friendly components. True to form, the onboard test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback